Interestingly, recent work revealed that the combination of CDK4/6i and MEKi induces senescence in pancreatic ductal adenocarcinoma [50, 51] and suppressed tumor growth in Braf/MEK inhibitor-resistant melanoma [52]. Here, CDK4 is linked to melanoma.